Paper Details

  1. Home
  2. Paper Details

Clinical utility of plecanatide in the treatment of chronic idiopathic constipation.

Author: BrowningDarren D, IslamBianca N, SharmanSarah K

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Constipation is a common problem that can affect quality of life. Some new drugs that target a protein in the gut called GC-C have been developed to help treat constipation. These drugs work for about 20% of people but can cause diarrhea. While one drug, plecanatide, may have fewer side effects, it appears to work similarly to linaclotide. These drugs may have potential for treating other gut problems, such as pain and inflammation.
Paper Details　
Original Abstract of the Article :
Constipation is an important health burden that reduces the quality of life for countless millions of people. Symptom-centric therapeutics are often used to treat constipation due to unknown etiology, but in many cases, these drugs are either inadequate or have significant side effects. More recentl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089121/

データ提供：米国国立医学図書館（NLM）

Plecanatide: A New Hope for Chronic Constipation

Constipation, a common and often frustrating condition, can significantly impact quality of life. This research delves into the clinical utility of plecanatide, a synthetic peptide agonist for epithelial guanylyl cyclase C (GC-C), in the treatment of chronic idiopathic constipation. The authors compare plecanatide to linaclotide, another GC-C agonist, evaluating their effectiveness and side effect profiles. This study provides valuable insights into the potential of plecanatide as a safe and effective treatment option for constipation, contributing to the ongoing search for better therapeutic approaches for this common ailment.

A Targeted Approach: GC-C Agonists Offer New Possibilities

The study reveals the promising therapeutic potential of GC-C agonists, like plecanatide and linaclotide, in treating chronic idiopathic constipation. These drugs work by stimulating the production of cyclic GMP (cGMP), a signaling molecule that regulates intestinal motility. While both plecanatide and linaclotide exhibit similar clinical efficacy, plecanatide may offer a lower risk of diarrhea, a common side effect associated with these medications.

Beyond Constipation: Expanding the Horizons

The study highlights the potential of GC-C agonists beyond treating constipation. The authors propose that cGMP signaling components could serve as diagnostic markers for functional bowel disorders and that modulating cGMP levels could hold promise for treating other gastrointestinal conditions, such as enteric pain and ulcerative colitis. This research opens up a new avenue for exploring the therapeutic potential of GC-C agonists in a broader range of gastrointestinal diseases.

Dr.Camel's Conclusion

Constipation is like a stubborn sand dune, blocking the smooth flow of life. Plecanatide, like a gentle desert breeze, can help to shift those dunes, restoring a sense of normalcy. This research is a testament to the ongoing search for effective and safe treatments for common ailments, paving the way for a more comfortable and fulfilling life.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-09-28
Further Info :

Pubmed ID

30127634

DOI: Digital Object Identifier

PMC6089121

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.